糖皮质激素受体在肝癌细胞生长中的作用机制

doi:10.3760/cma.j.cn371439-20230120-00047

国际肿瘤学杂志 ›› 2023, Vol. 50 ›› Issue (4): 241-243.doi: 10.3760/cma.j.cn371439-20230120-00047

糖皮质激素受体在肝癌细胞生长中的作用机制

李佳璇¹, 封颖璐²()

¹青岛大学医学部中西医结合中心，青岛 266071
²海军第971医院中医科，青岛 266071

收稿日期:2023-01-20 修回日期:2023-03-06 出版日期:2023-04-08 发布日期:2023-06-12
通讯作者: 封颖璐，Email： 18661990776@163.com
基金资助:
山东省自然科学基金(ZR2020MH390)

Mechanism of action of glucocorticoid receptors in the growth of hepatoma cells

Li Jiaxuan¹, Feng Yinglu²()

¹Integrative Chinese and Western Medicine Center， Qingdao University Medical College， Qingdao 266071， China
²Department of Traditional Chinese Medicine， No.971 Hospital of the PLA Navy， Qingdao 266071， China

Received:2023-01-20 Revised:2023-03-06 Online:2023-04-08 Published:2023-06-12
Contact: Feng Yinglu， Email： 18661990776@163.com
Supported by:
Natural Science Foundation of Shandong Province of China(ZR2020MH390)

摘要/Abstract

摘要：

糖皮质激素受体（GR）在癌细胞的信号转导、相关基因表达及凋亡中发挥十分关键的作用。肝癌具有侵袭性强、死亡率高的特征，在关于GR与肝癌关系的探索中，大量研究表明GR对肝癌细胞的生长有抑制作用，这为临床治疗肝癌提供了新思路和新方法。

关键词: 受体, 糖皮质激素, 肝肿瘤, 糖皮质激素类

Abstract:

The glucocorticoid receptor （GR） plays a critical role in signal transduction， expression of related genes and apoptosis of cancer cells. Hepatocellular carcinoma is characterized by high aggressiveness and mortality. In the exploration of the relationship between GR and hepatocellular carcinoma， numerous studies have shown that GR has an inhibitory effect on the growth of hepatocellular carcinoma cells， which provides new ideas and methods for the clinical application of GR in the treatment of hepatocellular carcinoma.

Key words: Receptors, glucocorticoid, Liver neoplasms, Glucocorticoids

李佳璇, 封颖璐. 糖皮质激素受体在肝癌细胞生长中的作用机制[J]. 国际肿瘤学杂志, 2023, 50(4): 241-243.

Li Jiaxuan, Feng Yinglu. Mechanism of action of glucocorticoid receptors in the growth of hepatoma cells[J]. Journal of International Oncology, 2023, 50(4): 241-243.

参考文献 24

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. doi: 10.3322/caac.21660
[2]	Meijer OC, Koorneef LL, Kroon J. Glucocorticoid receptor modulators[J]. Ann Endocrinol (Paris), 2018, 79(3): 107-111. DOI: 10.1016/j.ando.2018.03.004. doi: S0003-4266(18)30029-5 pmid: 29731108
[3]	Kalfeist L, Galland L, Ledys F, et al. Impact of glucocorticoid use in oncology in the immunotherapy era[J]. Cells, 2022, 11(5): 770. DOI: 10.3390/cells11050770. doi: 10.3390/cells11050770
[4]	Caratti B, Fidan M, Caratti G, et al. The glucocorticoid receptor associates with RAS complexes to inhibit cell proliferation and tumor growth[J]. Sci Signal, 2022, 15(726): eabm4452. DOI: 10.1126/scisignal.abm4452. doi: 10.1126/scisignal.abm4452
[5]	Vesting AJ, Jais A, Klemm P, et al. NIK/MAP3K14 in hepatocytes orchestrates NASH to hepatocellular carcinoma progression via JAK2/STAT5 inhibition[J]. Mol Metab, 2022, 66: 101626. DOI: 10.1016/j.molmet.2022.101626. doi: 10.1016/j.molmet.2022.101626
[6]	Whirledge S, DeFranco DB. Glucocorticoid signaling in health and disease: insights from tissue-specific GR knockout mice[J]. Endocrinology, 2018, 159(1): 46-64. DOI: 10.1210/en.2017-00728. doi: 10.1210/en.2017-00728 pmid: 29029225
[7]	Matthews LC, Berry AA, Morgan DJ, et al. Glucocorticoid receptor regulates accurate chromosome segregation and is associated with malignancy[J]. Proc Natl Acad Sci U S A, 2015, 112(17): 5479-5484. DOI: 10.1073/pnas.1411356112. doi: 10.1073/pnas.1411356112
[8]	Prekovic S, Schuurman K, Mayayo-Peralta I, et al. Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer[J]. Nat Commun, 2021, 12(1): 4360. DOI: 10.1038/s41467-021-24537-3. doi: 10.1038/s41467-021-24537-3 pmid: 34272384
[9]	Jiang Z, Zhang C, Liu X, et al. Dexamethasone inhibits stemness maintenance and enhances chemosensitivity of hepatocellular carcinoma stem cells by inducing deSUMOylation of HIF‑1α and Oct4[J]. Int J Oncol, 2020, 57(3): 780-790. DOI: 10.3892/ijo.2020.5097. doi: 10.3892/ijo.2020.5097 pmid: 32705164
[10]	Escoter-Torres L, Caratti G, Mechtidou A, et al. Fighting the fire: mechanisms of inflammatory gene regulation by the glucocorticoid receptor[J]. Front Immunol, 2019, 10: 1859. DOI: 10.3389/fimmu.2019.01859. doi: 10.3389/fimmu.2019.01859 pmid: 31440248
[11]	Timmermans S, Vandewalle J, Libert C. Dimerization of the glucocorticoid receptor and its importance in (patho)physiology: a primer[J]. Cells, 2022, 11(4): 683. DOI: 10.3390/cells11040683. doi: 10.3390/cells11040683
[12]	Morse MA, Sun W, Kim R, et al. The role of angiogenesis in hepatocellular carcinoma[J]. Clin Cancer Res, 2019, 25(3): 912-920. DOI: 10.1158/1078-0432.CCR-18-1254. doi: 10.1158/1078-0432.CCR-18-1254 pmid: 30274981
[13]	朱金霞, 刘光伟, 杨培伟. 中医药调控Wnt/β-catenin通路治疗肝细胞癌的研究进展[J]. 中国中医基础医学杂志, 2023, 29(4): 679-686. DOI: 10.19945/j.cnki.issn.1006-3250.2023.04.011. doi: 10.19945/j.cnki.issn.1006-3250.2023.04.011
[14]	Liu B, Zhou H, Zhang T, et al. Loss of endothelial glucocorticoid receptor promotes angiogenesis via upregulation of Wnt/β-catenin pathway[J]. Angiogenesis, 2021, 24(3): 631-645. DOI: 10.1007/s10456-021-09773-x. doi: 10.1007/s10456-021-09773-x pmid: 33650028
[15]	Marchi D, van Eeden FJM. Homeostatic regulation of glucocorticoid receptor activity by hypoxia-inducible factor 1: from physiology to clinic[J]. Cells, 2021, 10(12): 3441. DOI: 10.3390/cells10123441. doi: 10.3390/cells10123441
[16]	Tian H, Zhu X, Lv Y, et al. Glucometabolic reprogramming in the hepatocellular carcinoma microenvironment: cause and effect[J]. Cancer Manag Res, 2020, 12: 5957-5974. DOI: 10.2147/CMAR.S258196. doi: 10.2147/CMAR.S258196 pmid: 32765096
[17]	Greulich F, Hemmer MC, Rollins DA, et al. There goes the neighborhood: assembly of transcriptional complexes during the regulation of metabolism and inflammation by the glucocorticoid receptor[J]. Steroids, 2016, 114: 7-15. DOI: 10.1016/j.steroids.2016.05.003. doi: S0039-128X(16)30035-6 pmid: 27192428
[18]	Ma R, Zhang W, Tang K, et al. Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma[J]. Nat Commun, 2013, 4: 2508. DOI: 10.1038/ncomms3508. doi: 10.1038/ncomms3508 pmid: 24149070
[19]	Cho JH, Lee YM, Starost MF, et al. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ⅰa at the tumor-developing stage[J]. J Inherit Metab Dis, 2019, 42(3): 459-469. DOI: 10.1002/jimd.12056. doi: 10.1002/jimd.12056
[20]	Feng J, Li J, Wu L, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2020, 39(1): 126. DOI: 10.1186/s13046-020-01629-4. doi: 10.1186/s13046-020-01629-4
[21]	Du D, Liu C, Qin M, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma[J]. Acta Pharm Sin B, 2022, 12(2): 558-580. DOI: 10.1016/j.apsb.2021.09.019. doi: 10.1016/j.apsb.2021.09.019 pmid: 35256934
[22]	Gnocchi D, Sabbà C, Massimi M, et al. Metabolism as a new avenue for hepatocellular carcinoma therapy[J]. Int J Mol Sci, 2023, 24(4): 3710. DOI: 10.3390/ijms24043710. doi: 10.3390/ijms24043710
[23]	Xu L, Xia H, Ni D, et al. High-dose dexamethasone manipulates the tumor microenvironment and internal metabolic pathways in anti-tumor progression[J]. Int J Mol Sci, 2020, 21(5): 1846. DOI: 10.3390/ijms21051846. doi: 10.3390/ijms21051846
[24]	Tahmasebi-Birgani M, Ansari H, Carloni V. Defective mitosis-linked DNA damage response and chromosomal instability in liver cancer[J]. Biochim Biophys Acta Rev Cancer, 2019, 1872(1): 60-65. DOI: 10.1016/j.bbcan.2019.05.008. doi: 10.1016/j.bbcan.2019.05.008

糖皮质激素受体在肝癌细胞生长中的作用机制

Mechanism of action of glucocorticoid receptors in the growth of hepatoma cells

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 24

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[2]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[3]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[4]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[5]	向玉玲, 谭佳杰, 熊远果, 赵丽蓉, 黎晨, 张洪. 脱水淫羊藿素对肝癌细胞增殖、迁移和凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(9): 513-519.
[6]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[7]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[8]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[9]	张丽, 向卓, 王强, 毕经旺. CAR-T免疫治疗相关的细胞因子释放综合征研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 377-381.
[10]	丁浩, 应劲涛, 付茂勇. CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	宁婷婷, 胡钦勇, 李倩, 杨鹏程. 奥希替尼与埃克替尼一线治疗EGFR阳性转移性NSCLC临床疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 65-70.
[13]	张碧霞, 丁江华. EGFR突变型非小细胞肺癌EGFR-TKI获得性耐药后免疫治疗现状[J]. 国际肿瘤学杂志, 2023, 50(2): 97-101.
[14]	于晓鹏, 冯青青, 赵文飞, 赵文文, 魏红梅. 靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J]. 国际肿瘤学杂志, 2023, 50(10): 631-635.
[15]	许婷婷, 胡超苏, 李宝生. 抗EGFR单抗治疗局部晚期头颈部鳞状细胞癌临床共识（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(1): 1-11.